Jović Z, Janković SM, Ružić Zečević D, Milovanović D, Stefanović S, Folić M, et al. Clinical pharmacokinetics of second-generation triazoles for the treatment of invasive aspergillosis and candidiasis. Eur J Drug Metab Pharmacokinet 2019;44:139–57.CrossrefPubMedWeb of ScienceGoogle Scholar
Desai A, Yamazaki T, Dietz AJ, Kowalski D, Lademacher C, Pearlman H, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev 2017;6:86–92.Web of SciencePubMedCrossrefGoogle Scholar
Andes DR, Ghannoum MA, Mukherjee PK, Kovanda LL, Lu Q, Jones ME, et al. Outcomes by MIC values for patients treated with isavuconazole or voriconazole for invasive aspergillosis in the phase 3 SECURE and VITAL trials. Antimicrob Agents Ch 2018;63. pii: e01634-18.Web of ScienceGoogle Scholar
Billaud EM, Guillemain R, Berge M, Amrein C, Lefeuvre S, Louët AL, et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 2010;48(Suppl 1):S52–9.PubMedCrossrefWeb of ScienceGoogle Scholar
Kabulski GM, MacVane SH. Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation. Transpl Infect Dis 2018;20:e12878.Web of ScienceCrossrefGoogle Scholar
Cozzi V, Baldelli S, Castoldi S, Clementi E, Cattaneo D. Development and validation of a chromatographic ultraviolet method for the quantification of isavuconazole in human plasma samples. Ther Drug Monit 2018;40:512–4.PubMedWeb of ScienceCrossrefGoogle Scholar
Arsiè E, Piconi S, Iavarone M, Cozzi V, Lampertico P, Cattaneo D. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis. Eur J Clin Pharmacol 2018;74:1089–90.Web of ScienceCrossrefGoogle Scholar
About the article
Published Online: 2019-05-29
Published in Print: 2019-10-25
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.